Current antithrombotic treatment in east Asia: Some perspectives on anticoagulation and antiplatelet therapy

Thrombosis and Haemostasis

Volumn 107, Issue 6, 2012, Pages 1014-1018

  Ma, Changsheng ^a  

^a CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ACETYLSALICYLIC ACID PLUS CLOPIDOGREL; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; APIXABAN; CILOSTAZOL; CLOPIDOGREL; DABIGATRAN; PLACEBO; RIVAROXABAN; THIENOPYRIDINE DERIVATIVE; TICLOPIDINE; WARFARIN;

ACUTE CORONARY SYNDROME; ANTICOAGULATION; ARTICLE; ASIA; ATHEROSCLEROSIS; BLEEDING; BRAIN HEMORRHAGE; BRAIN INFARCTION; BRAIN ISCHEMIA; CORONARY ARTERY ATHEROSCLEROSIS; DEATH; DRUG DOSE COMPARISON; DRUG ELUTING STENT; GASTROINTESTINAL HEMORRHAGE; HEART ATRIUM FIBRILLATION; HEART DEATH; HEART INFARCTION; HUMAN; IMPLANTATION; INTERNATIONAL NORMALIZED RATIO; LIVER DYSFUNCTION; LOW DRUG DOSE; PREVALENCE; PRIORITY JOURNAL; REVASCULARIZATION; RISK; SIDE EFFECT; STENT THROMBOSIS; STROKE; THROMBOEMBOLISM; TRANSIENT ISCHEMIC ATTACK;

AGED; ANGIOPLASTY, BALLOON, CORONARY; ANTICOAGULANTS; ASIAN CONTINENTAL ANCESTRY GROUP; ATRIAL FIBRILLATION; BLOOD COAGULATION; FAR EAST; FIBRINOLYTIC AGENTS; HUMANS; MIDDLE AGED; PLATELET AGGREGATION INHIBITORS; PRACTICE GUIDELINES AS TOPIC; PRIMARY PREVENTION; RISK ASSESSMENT; RISK FACTORS; STROKE; THROMBOSIS; TREATMENT OUTCOME;

EID: 84861739082     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH11-04-0214     Document Type: Article

References (60)

1. Goto S, Ikeda Y, Chan JCN, et al. Risk-factor profile, drug usage and cardiovascular events within a year in patients with and at high risk of atherothrombo-sis recruited from Asia as compared with those recruited from non-Asian regions: a substudy of the REduction of Atherothrombosis for Continued Health (REACH) registry. Heart Asia 2011; 3: 93-98.
2. Goto SH, Hankey G, Hills MT, et al. How can we avoid a stroke crisis in the Asia-Pacific region? Working Group Report: Stroke prevention in patients with atrial fibrillation. Chameleon Communications International, London; 2011. Available at: http://www.atrialfibrillation.org.uk/files/file/Articles_Medical/110413%20 Asia%20Pacific%20report.pdf.
3. Go AS, Hylek EM, Phillips KA, et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. J Am Med Assoc 2001; 285: 2370-2375.
4. Zhou Z, Hu D. An epidemiological study on the prevalence of atrial fibrillation in the Chinese population of mainland China. J Epidemiol 2008; 18: 209-216.
5. Yap KB, Ng T P, Ong HY. Low prevalence of atrial fibrillation in community-dwelling Chinese aged 55 years or older in Singapore: a population-based study. J Electrocardiol 2008; 41: 94-98.
6. Iguchi Y, Kimura K, Aoki J, et al. Prevalence of atrial fibrillation in community-dwelling Japanese aged 40 years or older in Japan: analysis of 41,436 non-employee residents in Kurashiki-city. Circ J 2008; 72: 909-913.
7. Jeong JH. Prevalence of and risk factors for atrial fibrillation in Korean adults older than 40 years. J Korean Med Sci 2005; 20: 26-30.
8. Chien KL, Su TC, Hsu HC, et al. Atrial fibrillation prevalence, incidence and risk of stroke and all-cause death among Chinese. Int J Cardiol 2010; 139: 173-180.
9. Tanizaki Y, Kiyohara Y, Kato I, et al. Incidence and risk factors for subtypes of cerebral infarction in a general population: the Hisayama study. Stroke 2000; 31: 2616-2622.
10. Ma CS, Zhou YJ, Ma Y, et al. A follow up study of incidence of stroke and risk factors in patients with nonvalvular atrial fibrillation in Beijing area. Chin J Cardiol (Chin) 2002; 30: 165-167.
11. Nakayama T, Date C, Yokoyama T, et al. A 15.5-year follow-up study of stroke in a Japanese provincial city. The Shibata Study. Stroke 1997; 28: 45-52.
12. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Fram-ingham Study. Stroke 1991; 22: 983-988.
13. Onundarson PT, Thorgeirsson G, Jonmundsson E, et al. Chronic atrial fibrillation--epidemiologic features and 14 year follow-up: a case control study. Eur Heart J 1987; 8: 521-527.
14. Shen AY, Ya o JF, Brar SS, et al. Racial/ethnic differences in the risk o f in tracranial hemorrh age among patients with atrial fibrillation. J Am Coll Cardiol 2007; 50: 309-315.
15. Sato H, Ishikawa K, Kitabatake A, et al. Low-dose aspirin for prevention of stroke in low-risk patients with atrial fibrillation: Japan Atrial Fibrillation Stroke Trial. Stroke 2006; 37: 447-451.
16. Hu D, Zhang H, Sun Y, et al. The randomized study of efficiency and safety of antithrombic therapy in nonvalvular atrial fibrillation:warfarin compared with aspirin. Chin J Cardiol 2006; 34: 295-298.
17. Yamaguchi T. Optimal intensity of warfarin therapy for secondary prevention of stroke in patients with nonvalvular atrial fibrillation: a multicenter, prospective, randomized trial. Japanese Nonvalvular At-rial Fibrillation-Embolism Secondary Prevention Cooperative Study Group. Stroke 2000; 31: 817-821.
18. Suzuki S, Yamashita T, Kato T, et al. Incidence of major bleeding complication of warfarin therapy in Japanese patients with atrial fibrillation. Circ J 2007; 71: 761-765.
19. Lip GY, Andreotti F, Fauchier L, et al. Bleeding risk assessment and management in atrial fibrillation patients. Executive Summary of a Position Document from the European Heart Rhythm Association [EHRA], endorsed by the European Society of Cardiology [ESC] Working Group on Thrombosis. Thromb Haemost 2011; 106: 997-1011.
20. Guidelines for pharmacotherapy of atrial fibrillation (JCS 2008): digest version. Circ J 2010; 74: 2479-2500.
21. Huang CX, Zhang S, Ma CS, et al. Current knowledge and management recommendations of atrial fibrillation-2010. Chin J Cardiac Arrhyth (Chin) 2010; 10: 328-367.
22. Furusho H, Takamura M, Takata S, et al. Current status of anticoagulation therapy for elderly atrial fibrillation patients in Japan: from Hokuriku atrial fibrillation trial. Circ J 2008; 72: 2058-2061.
23. Uchiyama S, Shibata Y, Hirabayashi T, et al. Risk factor profiles of stroke, myocardial infarction, and atrial fibrillation: a Japanese Multicenter Cooperative Registry. J Stroke Cerebrovasc Dis 2010; 19: 190-197.
24. Goto S, Bhatt DL, Rother J, et al. Prevalence, clinical profile, and cardiovascular outcomes of atrial fibrillation patients with atherothrombosis. Am Heart J 2008; 156: 855-863.
25. Faxon D P, Eikelboom JW, Berger PB, et al. Consensus document: antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting. A North-American perspective. Thromb Hae-most 2011; 106: 572-584.
26. Ahrens I, Lip G Y, Peter K. What do the RE-LY, AVERROES and ROCKET-AF trials tell us for stroke prevention in atrial fibrillation. Thromb Haemost 2011; 105: 574-578.
27. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabig-atran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361: 1139-1151.
28. Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011; 365: 883-891.
29. Granger CB, Alexander JH, McMurray JJ, et al. Api-xaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011; 365: 981-992.
30. Garcia DA, Lopes RD, Hylek EM. New-onset atrial fibrillation and warfarin initiation: high risk periods and implications for new antithrombotic drugs.Thromb Haemost 2010; 104: 1099-1105.
31. Iakovou I, Schmidt T, Bonizzoni E, et al. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. J Am Med Assoc 2005; 293: 2126-2130.
32. Park DW, Park SW, Park KH, et al. Frequency of and risk factors for stent thrombosis after drug-eluting stent implantation during long-term follow-up. Am J Cardiol 2006; 98: 352-356.
33. KSB, Smith SC, Hirshfeld JW, et al. 2007 Focused Update of the ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines: 2007 Writing Group to Review New Evidence and Update the ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention, Writing on Behalf of the 2005 Writing Committee. Circulation 2008; 117: 261-295.
34. Park SJ, Park DW, Kim YH, et al. Duration of dual antiplatelet therapy after implantation of drug-eluting stents. N Engl J Med 2010; 362: 1374-1382.
35. Chen WH, Cheng X, Lee P Y, et al. Aspirin resistance and adverse clinical events in patients with coronary artery disease. Am J Med 2007; 120: 631-635.
36. Chen WH, Lee PY, Ng W, et al. Aspirin resistance is associated with a high incidence of myonecrosis after non-urgent percutaneous coronary intervention despite clopidogrel pretreatment.J Am Coll Cardiol 2004; 43: 1122-1126.
37. Hoshino K, Horiuchi H, Tada T, et al. Clopidogrel resistance in Japanese patients scheduled for percutaneous coronary intervention.Circ J 2009; 73: 336-342.
38. Wang ZJ, Zhou YJ, Liu YY, et al.Impact of clopido-grel resistance on thrombotic events after percutaneous coronary intervention with drug-eluting stent. Thromb Res 2009; 124: 46-51.
39. Wang L, Wang X, Chen F. Clopidogrel resistance is associated with long-term thrombotic events in patients implanted with drug-eluting stents. Drugs RD 2010; 10: 219-224.
40. Shinohara Y, Gotoh F, Tohgi H, et al. Antiplatelet ci-lostazol is beneficial in diabetic and/or hypertensive ischemic stroke patients. Subgroup analysis of the cilostazol stroke prevention study. Cerebrovasc Dis 2008; 26: 63-70.
41. Huang Y, Cheng Y, Wu J, et al. Cilostazol as an alternative to aspirin after ischaemic stroke: a randomised, double-blind, pilot study. Lancet Neurol 2008; 7: 494-499.
42. Jeong YH, Lee SW, Choi BR, et al. Randomized comparison of adjunctive cilostazol versus high maintenance dose clopidogrel in patients with high post-treatment platelet reactivity: results of the ACCEL-RESISTANCE (Adjunctive Cilostazol Versus High Maintenance Dose Clopidogrel in Patients With Clopidogrel Resistance) randomized study. J Am Coll Cardiol 2009; 53: 1101-1109.
43. Angiolillo DJ, Capranzano P, Goto S, et al. A randomized study assessing the impact of cilostazol on platelet function profiles in patients with diabetes mellitus and coronary artery disease on dual anti-platelet therapy: results of the OPTIMUS-2 study. Eur Heart J 2008; 29: 2202-2211.
44. Lee SW, Park SW, Hong MK, et al. Triple versus dual antiplatelet therapy after coronary stenting: impact on stent thrombosis. J Am Coll Cardiol 2005; 46: 1833-1837.
45. Lee SW, Park SW, Yun SC, et al. Triple antiplatelet therapy reduces ischemic events after drug-eluting stent implantation: Drug-Eluting stenting followed by Cilostazol treatment REduces Adverse Serious cardiac Events (DECREASE registry). Am Heart J 2010; 159: 284-291.e1.
46. Chen KY, Rha SW, Li YJ, et al. Triple versus dual antiplatelet therapy in patients with acute ST-seg-ment elevation myocardial infarction undergoing primary percutaneous coronary intervention. Circulation 2009; 119: 3207-3214.
47. Suh JW, Le e S P, Park KW, et al. Multicenter randomized trial evaluating the efficacy of cilostazol on ischemic vascular complications after drug-eluting stent implantation for coronary heart disease: results of the CILON-T (influence of CILostazol-based triple antiplatelet therapy ON ischemic complication after drug-eluting stenT implantation) trial. J Am Coll Cardiol 2011; 57: 280-289.
48. Han Y, Li Y, Wang S, et al. Cilostazol in addition to aspirin and clopidogrel improves long-term outcomes after percutaneous coronary intervention in patients with acute coronary syndromes: a randomized, controlled study. Am Heart J 2009; 157: 733-739.
49. Fukuuchi Y, Tohgi H, Okudera T, et al. A randomized, double-blind study comparing the safety and efficacy of clopidogrel versus ticlopidine in Japanese patients with noncardioembolic cerebral infarction. Cerebrovasc Dis 2008; 25: 40-49.
50. Uchiyama S, Fukuuchi Y, Yamaguchi T. The safety and efficacy of clopidogrel versus ticlopidine in Japanese stroke patients: combined results of two Phase III, multicenter, randomized clinical trials. J Neurol 2009; 256: 888-897.
51. Hirata K, Takagi H, Yamamoto M, et al. Ticlopidine-induced hepatotoxicity is associated with specific human leukocyte antigen genomic subtypes in Japanese patients: a preliminary case-control study. Pharmacogenomics J 2008; 8: 29-33.
52. Steg PG, Bhatt DL, Wilson PW, et al. One-year cardiovascular event rates in outpatients with athero-thrombosis. J Am Med Assoc 2007; 297:1197-1206.
53. Bhatt DL, Eagle KA, Ohman EM, et al. Comparative determinants of 4-year cardiovascular event rates in stable outpatients at risk of or with atherothrombo-sis. J Am Med Assoc 2010; 304: 1350-1357.
54. Song XT, Chen YD, Pan WQ, et al. Gender based differences in patients with acute coronary syndrome: findings from Chinese Registry of Acute Coronary Events (CRACE). Chin Med J (Engl) 2007; 120: 1063-1067.
55. Leong RW. Differences in peptic ulcer between the East and the West. Gastroenterol Clin North Am 2009; 38: 363-379.
56. Derry S, Loke YK. Risk of gastrointestinal haemorrhage with long term use of aspirin: Meta-analysis. Br Med J 2000; 321: 1183-1187.
57. Zaninelli A, Kaufholz C, Schwappach D. Physicians' attitudes toward post-MI aspirin prophylaxis: findings from an online questionnaire in Europe and Latin America. Postgrad Med 2009; 121: 44-53.
58. Zaninelli A, Hu DY, Kaufholz C, et al. Physicians' attitudes toward post-MI aspirin prophylaxis: findings from an online questionnaire in Asia-Pacific. Postgrad Med 2010; 122: 108-117.
59. Katakami N, Kim YS, Kawamori R, et al. The phosp-hodiesterase inhibitor cilostazol induces regression of carotid atherosclerosis in subjects with type 2 diabetes mellitus: principal results of the Diabetic Atherosclerosis Prevention by Cilostazol (DAPC) study: a randomized trial. Circulation 2010; 121: 2584-2591.
60. Teramoto T, Shimada K, Uchiyama S, et al. Rationale, design, and baseline data of the Japanese Primary Prevention Project-a randomized, open-label, controlled trial of aspirin versus no aspirin in patients with multiple risk factors for vascular events. Am Heart J 2010; 159: 361-369.